Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms
pharmaceutical investing Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing
pharmaceutical investing 1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
pharmaceutical investing Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
Allied Critical Metals Appoints General James A. "Spider" Marks as a Director of Allied Critical Metals USA, Its U.S. Subsidiary Focused on Tungsten Import and Sales
Questcorp Mining Completes 25 Percent of Maiden Drilling Program at the La Union Gold & Silver Project in Mexico
